New Drugs Approved In Japan Help Contain HBV Growth
This article was originally published in PharmAsia News
Among the 1.3 million to1.5 million hepatitis B carriers in Japan, 10 percent have developed full symptoms. Others usually live normally for years without symptoms; however, eventually most carriers develop into chronic hepatitis B patients. After GlaxoSmithKline's lamivudine was approved in Japan, 80 percent to 90 percent of patients who took the drug were virus free within a year and have normal liver function. However, long-term use of lamivudine can lead to drug resistance. Two other drugs approved in Japan, GSK's adefovir and Bristol-Myers Squibb's Baraclude are better at developing less resistance, but are more costly. (Click for more-Japanese language
You may also be interested in...
A new report focused on the European market says that winning trust is the key to taking AI adoption to the next stage. That approach was praised by MedTech Europe CEO Serge Bernasconi.
As the transition period following the UK’s withdrawal from the European Union draws to a close, cosmetics industry stakeholders are following final trade negotiations while readying themselves for new regulatory complexities.
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.